MiddleBrook Aims To Address $600 Million Strep Market With Moxatag
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans to launch the first once-daily amoxicillin formulation for patients over 12 in the fall.
You may also be interested in...
Advancis Gets Second Chance On Pulsatile Amoxicillin NDA
Firm plans to resubmit application with additional information in March.
Advancis Gets “Refuse To File” Letter For Pulsatile Amoxicillin NDA
Firm may need to manufacture commercial-sized quantities of antibiotic in order for FDA to accept the submission.
Advancis Likely To Change Name Following Ruling In Favor Of Sanofi-Aventis
Court rules that Advancis name infringes on Sanofi-Aventis' trademark and orders the two firms to submit a proposed order by Oct. 23.